Lyra reports BEACON Phase 2 smell-loss data: 0.87 improvement at week 24 (p=0.026)

Lyra Therapeutics, Inc.

BEACON Phase 2 trial: 0.87 improvement in smell loss vs control at week 24 (p=0.026) in patients with impaired smell at baseline.
Data filed in corporate presentation posted Jan 8, 2024; subset analysis shows statistically significant benefit.
No safety or additional efficacy details disclosed; further development plans not specified.
Lyra is a clinical-stage biotech focused on chronic rhinosinusitis therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.